Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

158.71 +0.81 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
48 49 Next >
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
From Biogen Inc.
Via GlobeNewswire
Biogen's Debt Overview
Via Benzinga
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... 
Via FinancialNewsMedia
Exposures COVID-19
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
It could be a make or break year for the biotech. 
Via The Motley Fool
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys. 
Via Investor's Business Daily
Biogen (BIIB) Q4 2022 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Via Benzinga
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, 
Via MarketBeat
Exposures COVID-19
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
Via Benzinga
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
The company is definitively closing the door on solanezumab. 
Via Investor's Business Daily
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. 
Via InvestorPlace
Why Biogen Stock Is Falling Today
Via Benzinga
Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales
The company expects "modest" Leqembi sales, but there's a caveat. 
Via Investor's Business Daily
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8
Looking for a bottom in wave {v} to then look for longs. 
Via Talk Markets
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
From Biogen Inc.
Via GlobeNewswire
Why Shares of Anavex Life Sciences Rose 12.4% in February
The company's first-quarter earnings report detailed positive news regarding its pipeline. 
Via The Motley Fool
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Via Benzinga
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
What Does Biogen's Debt Look Like?
Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
Peering Into Biogen's Recent Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that... 
Via Benzinga
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
From Biogen Inc.
Via GlobeNewswire
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
The FDA is set to review the company's neurological drug by Tuesday. 
Via Investor's Business Daily
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved'
Via Benzinga
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05. 
Via Talk Markets
Cisco, Analog Devices And 3 Stocks To Watch Heading Into Wednesday
With US futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
US Stocks Settle Mixed; Investor Optimism Improves
The CNN Money Fear and Greed index showed an improvement in the overall sentiment among US investors. 
Via Benzinga
Investors Are Awaiting The Name Of The New BoJ Governor
This week, the Japanese government will officially elect a new Governor of the Bank of Japan to replace Haruhiko Kuroda, whose decade at the Central Bank will end in April. 
Via Talk Markets
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS